Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting...

Area of Science:

• Oncology
• Immunology
• Inflammation Biology

Background:

• Targeted therapies and immune-checkpoint inhibitors (ICIs) have advanced non-small cell lung cancer (NSCLC) treatment.
• Patients without targetable mutations or with limited response to ICIs present a clinical challenge.
• Programmed death ligand 1 (PD-L1) expression predicts ICI response, but new biomarkers in the tumor microenvironment (TME) are needed.

Purpose of the Study:

• To review the role of interleukin-1 beta (IL-1β) in NSCLC.
• To explore IL-1β's involvement in inflammatory pathways and its crosstalk with the PD-1/PD-L1 pathway.
• To investigate the potential of IL-1β as a therapeutic target for NSCLC.

Main Methods:

• Literature review on IL-1β, inflammation, PD-1/PD-L1 pathway, and NSCLC.
• Analysis of the relationship between IL-1β, oncogenesis, and cancer development.
• Exploration of combinatorial approaches involving IL-1β inhibitors and ICIs.

Main Results:

• IL-1β is implicated in NSCLC development and influences patient outcomes.
• The IL-1β/PD-1/PD-L1 pathway is a key area of focus for understanding inflammation in NSCLC.
• Combinatorial strategies targeting IL-1β and PD-1/PD-L1 may benefit patients lacking targetable mutations.

Conclusions:

• IL-1β plays a significant role in NSCLC and inflammatory processes.
• Targeting the IL-1β/PD-1/PD-L1 pathway offers potential for novel NSCLC treatments.
• Further research is needed to overcome treatment resistance associated with this pathway.